Tracking AI use during AF ablation in real-world care
Part of Heart & circulation clinical trials.
This trial is for people with atrial fibrillation (AF) who are having or recently had a catheter ablation procedure. It looks at how using a special artificial intelligence tool, called VX1, during the procedure affects patient outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years of age or older.
- You are scheduled for or have already received a catheter ablation for AF (atrial fibrillation) within the past 2 years.
- During your ablation, a device called VX1 was used.
- You are willing and able to sign a consent form agreeing to participate.
- You are not pregnant or planning to become pregnant during the study.
- You are not currently taking part in another study for a different experimental device, drug, or biologic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an artificial intelligence (AI) system can help choose the best patients for a procedure called catheter ablation for atrial fibrillation (AF). It may improve which people benefit most while keeping safety in mind.
This study tests whether an AI software can help doctors identify which people with persistent atrial fibrillation might need more than just a standard ablation procedure. The software analyzes heart signals during the ablation to guide treatment, potentially improving outcomes for people whose condition is more complex.
This study tests new AI software (Volta AF-Xplorer II) that helps doctors guide catheter ablation—a procedure to treat irregular heartbeats like atrial fibrillation. The software may help doctors perform the procedure more effectively and safely in real-world settings.
This study tests advanced technology to improve how atrial fibrillation (AFib) is treated with a heart ablation procedure. It may help patients who are already advised to have AFib ablation by seeing how well the approach works in real clinical practice.
This trial tests a new catheter system to treat atrial fibrillation (AF) by creating small scars in the heart to block faulty signals. It may help people with symptoms that continue despite medication and who are scheduled for a standard ablation procedure.
This study tests a new imaging system (VERAFEYE) that helps doctors guide catheter ablation, a procedure to fix irregular heartbeats like atrial fibrillation. It aims to see if the system makes the procedure safer or more effective.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.